Stocks Register
Akebia Therapeutics Inc. (NASDAQ: AKBA) 5.38% Incline Turns Investors Away – Stocks Register
(NASDAQ:AKBA)’s beta value is holding at 0.83, while the average true range (ATR) indicator is currently reading 0.11. An analysis of the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock in terms ...
5 days ago
Knox Daily
Akebia Therapeutics Inc. [AKBA] CEO and President makes an insider sale of 46,570 shares worth 73,581. – Knox Daily
Earlier on March 31, 2022, Piper Sandler downgraded its rating. Their new recommendation was “a Neutral” for AKBA stock which previously was a “an Overweight”. Analyzing AKBA Stock Performance ...
6 hours ago
Insider Monkey via Yahoo
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
13 hours ago
Zacks via Yahoo
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
2 days ago
The Woonsocket Call
Akebia Therapeutics: Q1 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $18 million in its first quarter.
View all
akebia.com
More on Yahoo Finance